

CURRICULUM VITAE

Ronald Levy, M.D.

Personal Data

Citizenship	USA
Business Address	Division of Oncology, CCSR 1105 Stanford University Medical Center Stanford, California 94305-5151

Academic History

1963	Harvard University, A.B.
1968	Stanford University, M.D.

Post-Doctoral And Residency Training

1968-1970	Internship and Residency in Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts
1970-1972	Clinical Associate, Immunology Branch, National Cancer Institute
1972-1973	Fellow, Department of Medicine, Division of Oncology, Stanford University Medical Center, Stanford, California
1973-1975	Fellow of the Helen Hay Whitney Foundation, Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel

Certification And Licenses

1970	Commonwealth of Massachusetts
1973	Board Certification, Internal Medicine
1975	State of California Medical License #G021994
1979	Board Certification, Medical Oncology

Employment History

1970-1972	Clinical Associate, Immunology Branch, National Cancer Institute, Bethesda, Maryland
1975-1981	Assistant Professor of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California
1981-1987	Associate Professor of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California
1987-Present	Professor of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California
1987-Present	Robert K. Summy and Helen K. Summy Professor, Stanford University School of Medicine, Stanford, California

1987-Present	Frank and Else Schilling American Cancer Society Clinical Research Professor
1993-Present	Chief of the Division of Oncology, Stanford University School of Medicine, Stanford, California

Post-Degree Honors and Awards

1977-1982	Investigator, Howard Hughes Medical Institute
1979	Member, American Society of Clinical Investigation
1982	Armand Hammer Award for Cancer Research
1983	Ciba-Geigy/Drew Award in Biomedical Research
1987	Association of American Physicians
1987	American Cancer Society Clinical Research Professor
1989	Dr. Josef Steiner Prize for Cancer Research
1997	Joseph H. Burchenal Clinical Cancer Research Award, American Association for Cancer Research
1999	Karnofsky Award, American Society of Clinical Oncology
1999	Charles F. Kettering Prize, General Motors Cancer Research Foundation
1999	Centeon Award, 6th International Conference on Bispecific Antibodies
2000	C. Chester Stock Award, Memorial Sloan-Kettering Cancer Center
2000	Medal of Honor, American Cancer Society
2000	Key to the Cure Award, Cure for Lymphoma Foundation
2001	Evelyn Hoffman Memorial Award, Lymphoma Research Foundation of America
2003	Jeffrey A. Gottlieb Memorial Award, M.D. Anderson Cancer Center
2004	Donald Ware Waddell Award, Arizona Cancer Center
2004	J.E. Wallace Sterling Award, Stanford Medical Alumni Association
2004	Discovery Health Channel Medical Honoree, DAR Constitution Hall Washington DC
2005	Damashek Prize, American Society of Hematology
2006	iSBTc Richard V. Smalley Memorial Lectureship Award
2007	Member, Institute of Medicine of the National Academies
2007	di Villiers International Achievement Award, Leukemia and Lymphoma Society
2008	Member, National Academy of Science
2009	King Faisal International Prize, The King Faisal Foundation

Professional Review Activities

1988-1992	Chairman, American Cancer Society Immunology Study Section
-----------	--

1989-1993	Chairman, Board of Scientific Counselors, Division of Cancer Treatment, National Institute of Health
1992-1996	Program Committee and Block Chairman for Tumor Immunology, American Association of Immunology
1992-1996 and 2001-2004	General Motors Cancer Research Foundation Awards Assembly
2001	American Association of Medical Schools Task Force on Financial Conflicts of Interest in Clinical Research
2001	Dorothy P. Landon - American Association for Cancer Research Translational Cancer Research Prize Committee
2002	2002 Chairman, Joseph H. Burchinal Award Committee, American Association of Cancer Research
2002-2005	Margaret Early Trust
2002-2005	G&P Charitable Foundation Award
2002-2005	The V Foundation Award
2002-2007	Damon Runyon Clinical Investigators Award
2003-2007	Member Research Council, American Cancer Society
2004-2007	Board of Directors, American Association for Cancer Research
1994-Present	Scientific Advisory Board, Fred Hutchinson Cancer Research Center
2001-Present	Conflict of Interest Committee for Stanford University School of Medicine
2002-Present	Board of Directors, Damon Runyon Cancer Research Fund
2007-Present	Chairman, Rachleff Research Award, Damon Runyon Research Fund

Research Grant Committees

Margaret Early Trust
Lymphoma Research Foundation

Scientific Advisory Boards

Agensys, Santa Monica, CA
Cell Genesis, Foster City, CA
Five Prime, South San Francisco, CA
InNexus, Scottsdale, AZ
Angelica
Micromet, Bethesda, MD
Macrogenics, Bethesda, MD

Society Memberships

American College of Physicians
American Association for Cancer Research

American Society of Clinical Oncology
 American Association of Immunology
 American Federation for Clinical Research
 American Society of Clinical Investigation
 American Society of Hematology
 Western Society of Medicine
 Association of American Physicians
 Academy of Cancer Immunology

Major Research Interests

Immunology, Cancer Biology, Medical Oncology

Visiting Professorships

1994	Woodward Visiting Professor, Memorial Sloan Kettering Cancer Center, NY
1995	Morton Mason Lecture, University of Texas Southwestern
1996	University of Minnesota Cancer Center
1999	University of Nebraska Cancer Center
2007	William J. Harrington Visiting Professor, University of Miami

Invited Lectureships (last 3 years)

January 2005	Lecture, Tumor Immunology, Stanford, CA
February 2005	Keystone Symposia, Antibody-Base Therapeutics for Cancer, Santa Fe, New Mexico
March 2005	Keystone Symposium, Basic Aspects of Tumor Immunology II, Keystone Colorado
March 2005	Inaugural Joint American-Israeli Conference on Cancer, Israel Cancer Association-Israel, Jerusalem Israel
April 2005	Immunology 96 th AACR Annual, From Science to therapy, Anaheim, Orange County, CA
June 2005	Universitetet I Oslo , Immunotherapy of Lymphoma, Oslo Norway
September 2005	Translational Immunology Related To Cancer, Immunotherapy of Lymphoma, Bethesda MD
February 2006	University of Maryland, Immunotherapy of Lymphoma, College Park, Maryland
February 2006	International Cancer Vaccine Symposium, Cancer Vaccines and Immunotherapies, Washington DC
October 2006	iSBTC 21 st Annual Meeting, Therapeutic Vaccination for Lymphoid Malignancy
December 2006	ASH 48 th Annual Meeting and Exposition, Orlando, Florida
January 2007	Keystone Symposia Scientific Advisory Board, Immunological Intervention in Human Disease, Big Sky, Montana

February 2007	FDA/NCI Sponsored Workshop, Bring Therapeutic Cancer Vaccines and Immunotherapies Through Development to Licensure, Bethesda, Maryland
March 2007	Follicular Lymphoma, Vaccines, North Berwick, Scotland
October 2007	Hematology Society of Australia and New Zealand Annual Scientific Meeting, Lymphoma Vaccines & Lymphoma Vaccines: tricks of the trade, Gold Coast, Australia
October 2008	Nordic Lymphoma Meeting, Vaccine strategies against lymphomas – how far have we reached and prospects for the future, Helsinki, Finland.
November 2008	Leukaemia Research Fund, Grantholders Day and Annual Guest Lecture, Immunotherapy of lymphoma; from the passive to the active, London, England.
November 2008	The Leukemia & Lymphoma Society, Stohlman Scholar Scientific Symposium 2008, Using the Immune system to treat Lymphoma, Kansas City, Missouri
March 2009	The King Faisal Foundation, King Faisal Specialist Hospital and Research Center, Using the Immune system to treat Lymphoma, Riyadh, Saudi Arabia
March 2010	14th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myelomas, Whistler, BC, Canada
June 2010	Federation of Clinical Immunology Societies, FOCIS 10th Anniversary Session, Boston MA

PUBLICATIONS

1. Fulco AJ, **Levy R** and Block K: The biosynthesis of 9 and 5 monosaturated fatty acids by bacteria. **J Biol Chem** 239:998–1003, 1964.
2. McKhann GM, **Levy R** and Ho W: Metabolism of sulfatides. I. The effect of galactocerebrosides on the synthesis of sulfatides. **Biochem and Biophys Res Comm** 20:109–113, 1965.
3. Stossel TP and **Levy R**: Intravascular coagulation associated with pneumococcal bacteremia and symmetrical peripheral gangrene. **Arch Intern Med** 125:876–878, 1970.

1972

4. **Levy R** and Rosenberg SA: The early stimulation of protein synthesis in sensitized guinea pig lymph node cells by antigen. **J Immunol** 108:1073–1079, 1972.
5. Rosenberg SA and **Levy R**: A rapid assay of cell mediated immunity to soluble antigens based on the stimulation of protein synthesis. **J Immunol** 109:1080, 1972.
6. Rosenberg SA, **Levy R**, Schechter B, Ficker S and Terry WD: A rapid microassay of cellular immunity in the guinea pig and mouse. **Transplantation** 13:541–545, 1972.

7. Rosenberg SA and **Levy R**: Synthesis of nuclear-associated proteins by lymphocytes within minutes after contact with phytohemagglutinin. **J Immunol** 108:1105–1109, 1972.

1973

8. **Levy R** and Rosenberg SA: Protein synthesized in lymphoid cells early after activation by phytohemagglutinin. **Cell Immunol** 7:92–107, 1973.
9. **Levy R**, Levy S, Rosenberg SA and Simpson RT: Selective stimulation of nonhistone chromatin protein synthesis in lymphoid cells by phytohemagglutinin. **Biochemistry** 12:224–228, 1973.
10. Schechter B, Rosenberg SA, **Levy R**, Ficker S and Terry W: Early evaluation of mixed leukocyte interaction in mice and guinea pigs using measurements of protein synthesis. **Cell Immunol** 6:261–272, 1973.

1975

11. **Levy R**, Hurwitz E, Maron R, Arnon R and Sela M: The specific cytotoxic effects of daunomycin conjugated to anti-tumor antibodies. **Cancer Res** 35:1182–1186, 1975.

1976

12. Gabbay EJ, Grier D, Fingerle RE, Reimer R, **Levy R**, Pearce SW and Wilson WD: Interaction specificity of the anthracyclines with DNA. **Biochemistry** 15:2062–2070, 1976.

1977

13. **Levy R**, Warnke R, Dorfman RF and Haimovich J: The monoclonality of human B cell lymphomas. **J Exp Med** 145:1014–1027, 1977.
14. **Levy R** and Dilley J: The in vitro antibody response to cell surface antigens. I. The xenogeneic response to human leukemia cells. **J Immunol** 119:387–393, 1977.
15. **Levy R** and Dilley J: The in vitro antibody response to cell surface antigens. II. Monoclonal antibodies to human leukemia cells. **J Immunol** 119:394–400, 1977.
16. Lampson LA, Royston I and **Levy R**: Homogeneous antibodies directed against human cell surface antigens. I. The mouse spleen fragment culture response to T and B cell lines derived from the same individual. **J Supramolecular Struct** 6:441–448, 1977.

1978

17. Lampson LA, **Levy R**, Grumet FC, Ness D and Pious D: Production in vitro of murine antibody to a human histocompatibility alloantigen. **Nature** 271:461–462, 1978.
18. Warnke R and **Levy R**: Immunopathology of follicular lymphomas. A model of B lymphocyte homing. **New Eng J Med** 298:481–486, 1978.
19. **Levy R** and Dilley J: Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization. **Proc Natl Acad Sci** 75:2411–2415, 1978.
20. Kadin ME, Stites DP, **Levy R** and Warnke R: Exogenous immunoglobulin and the macrophage origin of Reed-Sternberg cells in Hodgkin's disease. **New Eng J Med** 299:1208–1214, 1978.

21. Epstein AL, **Levy R**, Kin H, Henle W, Henle G and Kaplan HS: Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines. **Cancer** 42:2379–2391, 1978.
22. Warnke R, Pederson M, Williams C and **Levy R**: A study of lymphoproliferative diseases comparing immunofluorescence with immunohistochemistry. **Amer J Clin Path** 70:867–875, 1978.
23. Merigan TC, Sikora K, Breeden JH, **Levy R** and Rosenberg SA: Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. **New Eng JMed** 299:1449–1453, 1978.

1979

24. Lampson LA and **Levy R**: A role for clonal antigens in cancer diagnosis and therapy. **J Natl Cancer Inst** 62:217–219, 1979.
25. Sikora K, Krikorian J and **Levy R**: Monoclonal immunoglobulin rescue from a patient with chronic lymphocyte leukemia and autoimmune hemolytic anemia. **Blood** 54: 513–517, 1979.
26. **Levy R**, Dilley J, Fox RI and Warnke R: A human thymus-leukemia antigen defined by hybridoma monoclonal antibodies. **Proc Natl Acad Sci** 76:6552–6556, 1979.

1980

27. Lampson LA and **Levy R**: Two populations of Ia-like molecules on human B cell line. **J Immunol** 125:293–299, 1980.
28. Warnke R, Miller R, Grogan T, Pederson M, Dilley J and **Levy R**: Immunologic phenotype in 30 patients with diffuse large cell lymphoma. **New Eng J Med** 303:293–300, 1980.
29. Brown S, Dilley J and **Levy R**: Immunoglobulin secretion by mouse x human hybridomas. An approach for the production of anti-idiotypic reagents useful in monitoring patients with B cell lymphoma. **J Immunol** 125:1037–1043, 1980.
30. Warnke R and **Levy R**: Detection of T and B cell antigens with hybridoma monoclonal antibodies. A biotin-avidin-horseradish peroxidase method. **J Histochem and Cytochem** 28:771–776, 1980.
31. Rich RR, Abramson SL, Seldin MF, Puck JM and **Levy R**: Role of Ia-positive cells in induction of secondary human immune responses to Haptens in vitro. **J Exp Med** 152(2):218S–234S, 1980.
32. Sikora K, Dilley J, Basham T, **Levy R** and Merigan T: Inhibition of lymphoma hybrids by human interferon. **The Lancet**, 891–893, October 25, 1980.
33. Goodfellow P, Banting F, **Levy R**, Povey S and McMichael A: A human x-linked antigen defined by a monoclonal antibody. **Somatic Cell Genetics** 6:777–787, 1980.
34. Grumet FC, Charron DJ, Fendly BM, **Levy R** and Ness DB: HLA-DR epitope region definition by use of monoclonal antibody probes. **J Immunol** 125:2785–2789, 1980.

1981

35. Engleman EG, Warnke R, Fox RI, Dilley J, Benike CJ and **Levy R**: Studies of a human T lymphocyte antigen recognized by a monoclonal antibody. **Proc Natl Acad Sci** 78:1791–1795, 1981.
36. Zipf TF, Fox RI, Dilley J and **Levy R**: Definition of the high risk acute lymphoblastic leukemia patient by immunological phenotyping with monoclonal antibodies. **Cancer Research** 41:4786–4789, 1981.
37. Hatzubai A, Maloney DG and **Levy R**: The use of a monoclonal anti-idiotypic antibody to study the biology of a human B cell lymphoma. **J Immunol** 126:2397–2402, 1981.
38. Miller RA, Maloney DG, McKillop J and **Levy R**: In vivo effects of murine hybridoma monoclonal antibody in a patient with T cell leukemia. **Blood** 58:78–86, 1981.
39. Miller RA and **Levy R**: Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. **The Lancet**, 226–229, August 1, 1981.
40. Neubauer RH, **Levy R**, Strnad BC and Rabin H: Reactivity of monoclonal antibodies against human leucocyte antigens with lymphocytes of non-human primate origin. **J Immunogenetics** 8:433–442, 1981.
41. Louie AC, Gallagher JG, Sikora K, **Levy R**, Rosenberg SA and Merigan TC: Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. **Blood** 58:712–718, 1981.
42. **Levy R**, Bergman Y and Finn OJ: Hybridoma monoclonal antibodies in the analysis of human cell surface antigens. **In Vitro** 17:1051–1057, 1981.

1982

43. Bergman Y and **Levy R**: Biosynthesis and processing of a human T lymphocyte antigen. **J Immunol** 128:1334–1340, 1982.
44. Wood GS, Deneau DG, Miller RA, **Levy R**, Hoppe RT and Warnke RA: Sub-types of cutaneous T cell lymphoma defined by expression of Leu-1 and Ia. **Blood** 59:876–882, 1982.
45. Miller RA, Maloney DG, Warnke R and **Levy R**: Treatment of B cell lymphoma with monoclonal anti-idiotypic antibody. **New Eng J Med** 306:517–522, 1982.
46. Finn OJ and **Levy R**: Multiple HLA-DR antigens: Detection with monoclonal antibodies and translation *in vitro*. **Proc Natl. Acad Sci** 79:2658–2662, 1982.
47. Dvoretzky P, Wood GS, **Levy R** and Warnke RA: T lymphocyte subsets in follicular lymphomas compared to those in non-neoplastic lymph nodes and tonsils. **Human Path** 13:618–625, 1982.
48. Hurley CK, Nunez G, Winchester R, Finn OJ, **Levy R** and Capra, JD: The human HLA-DR antigens are encoded by multiple beta-chain loci. **J Immunol** 129:2103–2108, 1982.
49. Stratte PT, Miller RA, Amyx HL, Asher DM and **Levy R**: In vivo effects of murine monoclonal anti-human T cell antibodies in subhuman primates. **J Biol Response Modifiers** 1:137–148, 1982.

50. Kaizer H, **Levy R**, Brovall C, Civin CI, Fuller DJ, Hsu SH, Leventhal BG, Miller RA, Milvenan ES, Santos GW and Wharam MD: Autologous bone marrow transplantation in T cell malignancies: A case report involving in vitro treatment of marrow with a Pan-T cell monoclonal antibody. **J Biol Resp Mod** 1:233–243, 1982.

1983

51. **Levy R** and Miller RA: Tumor therapy with monoclonal antibodies. **Federation Proceedings** 42:2650–2656, 1983.
52. Link MP, Roper M, Dorfman RF, Crist WM, Cooper MD and **Levy R**: Cutaneous lymphoblastic lymphoma with pre-B markers. **Blood** 61:838–841, 1983.
53. Bergman Y, Stewart SJ, Levy S and **Levy R**: Biosynthesis, glycosylation and in vitro translation of the human T cell antigen Leu-4. **J Immunol** 131:1876–1881, 1983.
54. Fujimoto J, Levy S and **Levy R**: Spontaneous release of the Leu-2 (T8) molecule from human T cells. **J Exp Med** 159:752–766, 1983.
55. Link M, Warnke R, Finlay J, Amylon M, Miller R, Dilley J and **Levy R**: A single monoclonal antibody identified T cell lineage of childhood lymphoid malignancies. **Blood** 62:722–728, 1983.
56. Miller RA, Oseroff AR, Stratte PT and **Levy R**, Monoclonal antibody therapeutic trials in seven patients with T cell lymphoma. **Blood** 62:988–995, 1983.
57. Wood GS, Burke JS, Horning S, Doggett RS, **Levy R** and Warnke RA: The immunologic and clinicopathologic heterogeneity of cutaneous lymphomas other than mycosis fungoides. **Blood** 62:464–472, 1983.
58. **Levy R**, Miller RA, Biological and clinical implications of lymphocyte hybridomas: tumor therapy with monoclonal antibodies. *Annu Rev Med.* 1983;34:107-16.

1984

59. Wood GS, Link M, Warnke RA, Dilley J and **Levy R**: Pan-leukocyte monoclonal antibody L3B12: Characterization and application to research and diagnostic problems. **Amer J Clin Path** 81:176–183, 1984.
60. Sklar J, Cleary ML, Thielemans K, Gralow J, Warnke R and **Levy R**: Biclinal B cell lymphoma. **New Eng J Med** 311:20–27, 1984.
61. Thielemans K, Maloney DG, Meeker T, Fujimoto JH, Doss C, Gralow J, Miller RA and **Levy R**: Strategies for production of monoclonal anti-idiotypic antibodies against human B cell lymphomas. **J Immunol** 133:495–501, 1984.
62. Fujimoto J, Stewart SJ and **Levy R**: Immunochemical analysis of the released Leu-2 (T8) molecule. **J Exp Med** 160:116–124, 1984.
63. Berenson RJ, Levitt LJ, **Levy R** and Miller RA: Cellular immunoabsorption using monoclonal antibodies: Selective removal of T cells from peripheral blood and bone marrow. **Transplantation** 38:136–143, 1984.
64. Doggett RS, Wood GS, Horning SJ, **Levy R**, Dorfman RF, Bindl J and Warnke RA: The immunological characterization of 95 nodal and extranodal large cell lymphomas in 89 patients. **Amer J Path** 115:245–252, 1984.

65. Horning SJ, Doggett RS, Warnke RA, Dorfman RF, Cox RS and **Levy R**: Clinical relevance of immunologic phenotype in diffuse large cell lymphoma. **Blood** 63:1209–1215, 1984.
66. Meeker TC, Miller RA, Link MP, Bindl J, Warnke R and **Levy R**: A unique human B lymphocyte antigen defined by a monoclonal antibody. **Hybridoma** 3:305–320, 1984.

1985

67. Meeker TC, Lowder JN, Maloney DG, Miller RA, Thielemans K, Warnke R and **Levy R**: A clinical trial of anti-idiotypic therapy for B cell malignancy. **Blood** 65:1349–1363, 1985.
68. Meeker T, Lowder J, Cleary ML, Stewart S, Warnke R, Sklar J and **Levy R**: Emergence of idiotype variants during therapy of B cell lymphoma with anti-idiotypic antibodies. **New Eng J Med** 312:1658–1665, 1985.
69. Link MP, Stewart SJ, Warnke RA and **Levy R**: Discordance between surface and cytoplasmic expression of the Leu-4 (T3) antigen in thymocytes and in blast cells from childhood T-lymphoblastic malignancies. **J Clin Invest** 76:248–253, 1985.
70. Thompson JM, Gralow JR, **Levy R** and Miller RA: The optimal application of forward and ninety-degree light scatter in flow cytometry for the gating of mononuclear cells. **Cytometry** 6:401–406, 1985.
71. Thielemans K, Rothbard JB, Levy S and **Levy R**: Syngeneic anti-idiotypic immune responses to a B cell lymphoma. Comparison between V_H hypervariable region peptides and intact immunoglobulin as immunogens. **J Exp Med** 162:19–34, 1985.
72. Garcia CF, Lowder J, Meeker TC, Bindl J, **Levy R** and Warnke RA: Differences in host infiltrates among lymphoma patients treated with anti-idiotypic antibodies: Correlation with treatment response. **J Immunol** 135:4252–4260, 1985.
73. Vaickus L and **Levy R**: Anti-proliferative monoclonal antibodies: Detection and initial characterization. **J Immunol** 135:1987–1997, 1985.
74. Maloney DG, Kaminski MS, Burowski D, Haimovich J and **Levy R**: Monoclonal anti-idiotypic antibodies against the murine B cell lymphoma 38C13: Characterization and use as probes for the biology of the tumor in vivo and in vitro. **Hybridoma** 4:191–209, 1985.
75. Liu MA, Kranz DM, Kurnick JT, Boyle LA, **Levy R** and Eisen HN: Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes. **Proc Natl Acad Sci** 82:8648–8653, 1985.
76. Hu E, Thompson J, Lowder JN, Horning S, **Levy R** and Sklar J: B lymphoma in peripheral blood detected by DNA hybridization. **The Lancet**, 1092–1095, November 16, 1985.

1986

77. Kaminski MS, Kitamura K, Maloney DG and **Levy R**: Importance of antibody isotype in monoclonal anti-idiotypic therapy of a murine B cell lymphoma: A study of hybridoma class switch variants. **J Immunol** 136:1123–1130, 1986.
78. Carroll WL, Thielemans K, Dilley J and **Levy R**: Mouse x human heterohybridomas as fusion partners with human B cell tumors. **J Immunol Methods** 89:61–72, 1986.

79. Cleary ML, Meeker TC, Levy S, Lee B, Trela M, Sklar J and **Levy R**: Clustering of extensive somatic mutations in the immunoglobulin heavy chain variable region gene of a human B cell lymphoma. **Cell** 44:97–106, 1986.
80. Campbell ML, Bieber M, **Levy R** and Teng NHH: Influence of avidity and idiotope recognition on the modulation of surface immunoglobulin on malignant human B cells by rat monoclonal anti-idiotypic antibodies. **J Immunol** 136:2983–2988, 1986.
81. Stewart S, Fujimoto J and **Levy R**: Human T lymphocytes and monocytes bear the same Leu-3(T4) antigen. **J Immunol** 136:3773–3778, 1986.
82. Link M, Bindl J, Meeker T, Carswell C, Doss C, Warnke R and **Levy R**: A unique antigen on mature B cell defined by a monoclonal antibody. **J Immunol** 137: 3013–3018, 1986.
83. Basham T, Kaminski MS, Kitamura K, **Levy R** and Merigan TC: Synergistic antitumor effect of interferon and anti-idiotypic monoclonal antibody in murine lymphoma. **J Immunol** 137:3019–3024.
84. Carroll WL, Lowder JN, Streifer R, Warnke R., Levy S and **Levy R**: Idiotypic variant cell populations in patients with B cell lymphoma. **J Exp Med** 164:1566–1580, 1986.

1987

85. Lowder J, Meeker T, Campbell M, Garcia C, Gralow J, Miller R, Warnke R and **Levy R**: Studies on B lymphoid tumors treated with monoclonal anti-idiotypic antibodies. Correlation with clinical responses. **Blood** 69:199–210, 1987.
86. Lowder JN, Miller RA, Hoppe R and **Levy R**: Suppression of anti-mouse immunoglobulin antibodies in primates receiving murine monoclonal antibodies against T cell antigens. **J Immunol** 138:401–406, 1987.
87. Kaminski MS, Kitamura K, Maloney DG and **Levy R**: Idiotypic vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. **J Immunol** 138:1289–1296, 1987.
88. Garcia CF, Weiss LM, Lowder J, Komorose C, Link MP, **Levy R** and Warnke RA: Quantitation and estimation of lymphocyte subsets in tissue sections: Comparison with flow cytometry. **Amer J Clin Path** 87:470–477, 1987.
89. Miller RA, Lowder JN, Gralow J, Meeker T and **Levy R**: In vitro tests which predict tumor-associated idiotype levels in the serum of patients with B cell lymphomas and leukemias. **Blood** 69:1249–1254, 1987.
90. Kon S, Levy S and **Levy R**: Retention of an idiotypic determinant in a human B-cell lymphoma undergoing immunoglobulin variable-region mutation. **Proc Natl Acad Sci USA** 84:5053–5057, 1987.
91. Maecker HT, Kitamura K, Brenner MB and **Levy R**: Isolation of anti-idiotypic antibodies to T cells using an anti-framework determinant antibody. **J Immunol Methods** 98:219, 1987.
92. Berinstein N and **Levy R**: Treatment of a murine B cell lymphoma with monoclonal antibodies and IL2. **J Immunol** 139:971–976, 1987.
93. Campbell MJ, Carroll W, Kon S, Thielemans K, Rothbard JB, Levy S and **Levy R**: Idiotypic vaccination against murine B cell lymphoma: Humoral and cellular responses elicited by tumor-derived IgM and its molecular subunits. **J Immunol** 139:2825–2833, 1987.

94. Berinstein N, Matthay KK, Papajadjopoulos D, **Levy R** and Sikic B: Antibody-directed targeting of liposomes to human cell lines: Role of binding and internalization on growth inhibition. **Cancer Research** 47:5954–5959, 1987.
95. Levy S, Kon S and **Levy R**: Somatic mutations in the Ig V_H genes of human B cell lymphoma. **Acta Paediatr Jpn** 29:561-565, 1987.

1988

96. Carroll WL, Link MP, Cleary ML, Bologna S, Carswell CC, Amylon MD, Smith SD and **Levy R**: Idiotype as a tumor specific marker in childhood B cell acute lymphoblastic leukemia. **Blood** 71:1068–1073, 1988.
97. Berinstein N, Starnes CO and **Levy R**: Specific enhancement of the therapeutic effect of anti-idiotypic antibodies on a murine B cell lymphoma by Interleukin 2. **J Immunol** 140:2839–2845, 1988.
98. Starnes CO, Carroll WL, Campbell MJ, Houston LL, Apell G and **Levy R**: Heterogeneity of a murine B cell lymphoma: Isolation and characterization of idiotypic variants. **J Immunol** 141:333–339, 1988.
99. Cleary ML, Galili N, Trela M, **Levy R** and Sklar J: Single cell origin of bi-genotypic and bi-phenotypic B-cell proliferations in human follicular lymphomas. **J Exp Med** 167:582–599, 1988.
100. Levy S, Mendel E, Kon S, Avnur Z and **Levy R**: Mutational hot-spots in immunoglobulin region genes of human follicular lymphomas. **J Exp Med** 168:475–489, 1988.
101. Basham TY, Palladino MA, Badger CC, Bernstein ID, **Levy R** and Merigan TC: Comparison of combinations of interferons with tumor specific and non-specific monoclonal antibodies as therapy for murine B and T cell lymphomas. **Cancer Research** 48:4196–4200, 1988.
102. Basham TY, Race ER, Campbell MJ, Reid TR, **Levy R**, and Merigan TC: Synergistic antitumor activity with IFN and monoclonal anti-idiotypic for murine B cell lymphoma. Mechanism of action. **J Immunol** 141:2855–2860, 1988.
103. Maecker H and **Levy R**: Spontaneous T cell antigen receptor variants of a human T leukemia cell line. **J Immunol** 141:2994–3002, 1988.
104. Campbell MJ, Esserman L and **Levy R**: Immunotherapy of established murine B cell lymphoma. **J Immunol**. 141:3227–3233, 1988.
105. Carroll WL, Starnes CO, **Levy R** and Levy S: Alternative V_K gene rearrangements in a murine B cell lymphoma. An explanation for idiotypic heterogeneity. **J Exp Med** 168:1607–1620, 1988.

1989

106. Brown SL, Miller RA, Horning SJ, Czerwinski D, Hart SM, McElderry R, Basham T, Warnke RA, Merigan TC and **Levy R**: Treatment of B cell lymphoma with anti-idiotypic antibodies alone and in combination with alpha interferon. **Blood** 73:651–661, 1989.
107. Maecker H and **Levy R**: Prevalence of antigen receptor variants in human T cell lines and tumors. **J Immunol** 142:1395–1404, 1989

108. Berinstein N, Levy S and **Levy R**: Activation of an excluded immunoglobulin allele in a human B lymphoma cell line. **Science** 244:337–339, 1989.
109. Wright A, Clayberger C, Link MP, Smith SD, **Levy R**, Brenner MB and Krensky AM Cytotoxic T lymphocytes specific for self tumor immunoglobulin express T cell receptor d chain. **J Exp Med** 169:1557–1564, 1989.
110. Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, **Levy R**, Miller R, Brown S, Nelp WB, Krohn KA, Fisher D, DeSantes K, Porter B, Kidd P, Thomas ED and Bernstein I. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. **J Clin Oncol** 7:1027–1038, 1989.
111. Levy S, Campbell MJ and **Levy R**: Functional immunoglobulin light chain genes are replaced by ongoing rearrangements of germline V_k genes to downstream J_k segments in a murine B cell line. **J Exp Med** 170:1–13, 1989.
112. Miller RA, Hart S, Samouszuk M, Coulter C, Kelkernberg J, Brown S, Czerwinski D, Royston I and **Levy R**: Shared idiotypes expressed by human B cell lymphomas. **New Eng J Med** 321:851–857, 1989.
113. Esserman L, Takahashi S, Rojas V, Warnke R and **Levy R**: An epitope of the transferrin receptor is exposed on the cell surface of high grade but not low grade human lymphomas. **Blood** 74:2718–2729, 1989.
114. Takahashi S, Maecker H T, and **Levy, R**. DNA fragmentation and cell death mediated by T cell antigen receptor/CD3 complex on a leukemia T cell line. **Eur. J. Immunol** 19: 1911–1919, 1989.

1990

115. Berinstein N, Campbell MJ, Lam K, Carswell C, Levy S and **Levy R**: Idiotypic variation in human B lymphoma cell line. **J Immunol** 144:752–758, 1990.
116. Umetsu, D. T., Esserman, L., Donlan, T. A., DeKruyff, R. H., and **Levy, R**. Induction of proliferation of human follicular (B-type) lymphoma cells by cognate interaction with a CD4+ T cell clone. **J. Immunol** 144: 2550–2557, 1990.
117. Zelenetz A and **Levy R**: Directional cloning of cDNA using a selectable Sfi I cassette. **Gene** 89:123–127, 1990
118. Oren R, Takahashi S, Doss C, **Levy R** and Levy S: TAPA-1, the target of an anti-proliferative antibody defines a new family of transmembrane proteins. **Mol Cell Bio** 10:4007–4015, 1990.
119. Knox, S. J., **Levy, R.**, Miller, R. A., Uhland, W., Schiele, J., Ruehl, W., Finston, R., Day-Lollini, P., and Goris, M. L. Determinants of the antitumor effect of radiolabeled monoclonal antibodies. **Cancer Res** 50: 4935–4940, 1990.
120. Kwak LW, Campbell MJ, Zelenetz AD, and **Levy R**: Combined syngeneic bone marrow transplantation and immunotherapy of a murine B cell lymphoma: Active immunization with tumor-derived idiotypic IgM . **Blood** 76:2411–2417, 1990.
121. Takahashi S, Doss C, Levy S, and **Levy R**. TAPA-1, the target of an antiproliferative antibody, is associated on the cell surface with the Leu-13 antigen. **J. Immunol** 145:2207–2213, 1990.

1991

122. Zelenetz A D, Chen TT, and **Levy, R**. Histologic transformation of follicular lymphoma to diffuse lymphoma represents tumor progression by a single malignant B cell. **J. Exp. Med** 173:197–207, 1991.
123. Takahashi S, L Esserman, and **Levy, R**. An epitope on the transferrin receptor preferentially exposed during tumor progression in human lymphoma is close to the ligand binding site. **Blood** 77:826–832, 1991.
124. Zelenetz AD, Campbell MJ, Bahler DW, Takahashi S, Oren R, Esserman L, Umetsu DT, Kwak LW, Maloney DG, Brown S, Chen TT, Andria ML, Levy S, Miller RA, and **Levy R**. Follicular lymphoma: A model of lymphoid tumor progression in man. **Annals of Oncology** 2:115–122, 1991.
125. Knox SJ, **Levy R**, Hodgkinson S, Bell R, Brown S, Wood GS, Hoppe R, Abel E A, Steinman L, Gaiser C , Young G , Bindl J , Hanham A, and Reichert T. Observations on the effect of Chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. **Blood** 77:20–30, 1991.
126. Berger RG, Knox SJ, **Levy R**, Sklar JL, Cohen P, and Reichert T. Mycosis Fungoides Arthropathy. **Annals of Internal Med** 114:571–572, 1991.
127. Stewart SJ and **Levy R**: Components of the human T lymphocyte antigen receptor complex, CD3-p28 and CD3-gamma, are biochemically distinct. **J Laboratory and Clinical Medicine** 114:394–400, 1991.
128. Eary J, Press O, Badger C, Durack L, Richter K, Addison S, Krohn K, Fisher D, Porter B, Williams D, Martin P, Appelbaum F, **Levy R**, Brown S, Miller R, Nelp W and Bernstein I: Imaging and treatment of B-cell lymphoma. **J Nuclear Med** 31: 1257–1268, 1991.
129. Dighiero G, Hart S, Lim A, Borch L, **Levy R**, and Miller RA: Autoantibody activity of immunoglobulins isolated from B-cell follicular lymphomas. **Blood** 78:581–585, 1991.
130. Kwak LW, Campbell MJ, Zelenetz AD and **Levy R**: Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: A strategy for using autologous marrow as an anti-tumor therapy. **Blood** 78:2768–2772, 1991.
131. Zelenetz AD, Chu G, Galilli N, Bangs CD, Horning S J, Donlon TA, Cleary ML, and **Levy R**. 1991. Enhanced detection of the t(14; 18)translocation in malignant lymphoma using pulsed-field gel electrophoresis. **Blood** 78:1552–1560, 1991.
132. Bahler DW, Campbell M J, Hart S, Miller R, Levy S, and **Levy R**: Ig VH gene expression among human follicular lymphomas. **Blood** 78:1561–1568, 1991.

1992

133. Campbell MJ, Zelenetz A D, Levy S, and **Levy R**. Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. **Molec Imm** 29:193–203, 1992.
134. Bahler DW, Gerry G, Oksenberg J, Warnke RA, and **Levy R**. Diversity of T cell antigen receptor variable genes used by mycosis fungoides cells. **Am J Path** 140:1–8, 1992.

135. Clayberger C, Luna-Fineman S, Lee JE, Pillai A, Campbell M, **Levy R** and Krensky AM. Interleukin 3 is a growth factor for human follicular B cell lymphoma. **J Exp Med** 175:371–376, 1992.
136. Bahler DW and **Levy R**, Clonal evolution of a follicular lymphoma: Evidence for antigen selection. **Proc Natl Acad Sci** 89:6770–6774, 1992.
137. Zelenetz AD, Chen TT, and **Levy R**, Clonal Expansion in follicular lymphoma occurs subsequent to antigenic selection. **J Exp Med** 176:1137–1148, 1992.
138. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, and **Levy R** Induction of immune responses in patients with B cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors. **N Eng J Med** 327: 1209–1215, 1992.
139. Maloney DG, Brown S, Czerwinski DK, Liles TM, Hart SM, Miller RA, and **Levy R** Monoclonal anti-idiotype antibody therapy of B cell lymphoma: The addition of a short course of chemotherapy does not prevent the emergence of idiotype negative variant cells. **Blood** 80:1502–1510, 1992.
140. Kwak LW, Campbell MJ, and **Levy R** Tumor resistance induced by syngeneic bone marrow transplantation and enhanced by Interleukin-2: A model for the graft versus leukemia reaction. **Cancer Research** 52:4117–4120, 1992.

1993

141. Zelenetz AD, Cleary ML and **Levy R** An interstitial deletion of chromosome 14 frequently occurs adjacent to the t(14; 18) translocation breakpoint in human follicular lymphoma . **Genes, Chromosomes and Cancer** 6:1–11, 1993.
142. Tao M-H and **Levy R** Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. **Nature** 362: 755–758, 1993.
143. Wood GS, Bahler DW, Hoppe RT, Warnke RA, Sklar JL and **Levy R** Transformation of mycosis fungoides: T-cell receptor b gene analysis demonstrates a common clonal origin for plaque-type mycosis fungoides and CD30⁺ large cell lymphoma. **J Investigative Derm** 101 (3):296–300, 1993.
144. Hsu F, Kwak L, Campbell M, Liles T, Czerwinski D, Hart S, Syrengelas A, Miller R, **Levy R** Clinical trials of idiotype-specific vaccine in B-cell lymphomas. **Annals of the NY Acad of Sci** 690:385–7, 1993.

1994

145. Renschler WF, Bhatt RR, Dower WJ and **Levy R** Synthetic peptide ligands of the antigen binding receptor induce programmed cell death in a human B-cell lymphoma. **Proc of the Nat Acad of Sci** 91(9):3623–7, 1994.
146. Vuist W, Maloney D, and **Levy R** Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce immunoglobulins signal transduction and is not prevented by tumor expression of high levels of Bcl-2 protein. **Blood**. Vol 83(4):899–906, 1994.
147. Maloney D, Liles T, Czerwinski D, Waldichuk C, Rosenberg J, Grillo-Lopez A, **Levy R** Phase I clinical trial using escalating single dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. **Blood** 84(8):2457–2466, 1994.

148. Chen T, Tao MH, **Levy R** Idiotype-cytokine fusion proteins as cancer vaccines. **J Immuno** 153:4775–4787, 1994.

1995

149. Chen T, **Levy R** Induction of autoantibody responses to GMCSF by hyperimmunization with an idiotype-GMCSF fusion protein. **J Immuno** 154:3105–3117, 1995.
150. Hsu F, **Levy R**, Preferential use of the VH4 immunoglobulin gene family by diffuse large cell lymphoma. **Blood** 86:3072-3082, 1995.
151. Renschler MF, Wada HG, Fok KS and **Levy R**, B-Lymphoma cells are activated by peptide ligands of the antigen binding receptor or by anti-idiotypic antibody to induce extracellular acidification. **Cancer Research** 55: 5642-5647, 1995.
152. Gross G, Levy S, **Levy R**, Waks T and Eshhar Z. Chimaeric T-cell receptors specific to a B-lymphoma idiotype: a model for tumor immunotherapy. **Biochemical Society Transactions** 23:2079-2082, 1995.

1996

153. Knox S, Hoppe R, Maloney D, Gibbs I, Fowler S, Marquex C, Cornbleet PJ, **Levy R** Treatment of cutaneous T cell lymphoma with chimeric anti-CD4 monoclonal antibody. **Blood** 87:893-899, 1996.
154. Hsu F, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, **Levy R** Vaccination of patients with B cell lymphoma using autologous antigen pulsed dendritic cells. **Nature Medicine** 2:52-58, 1996.
155. Knox S, Goris M, Trisler K, Negrin R, Davis T, Liles TM, Grillo-Lopez A, Chinn P, Varns C, Ning SC, Fowler S, Deb N, Becker M, Marquez C, and **Levy R** Yttrium-90-labeled Anti-CD20 Monoclonal Antibody Therapy of Recurrent B-Cell Lymphoma. **Clinical Cancer Research** 2:457-470, 1996.
156. Nelson E, Li X, Hsu F, Kwak L, **Levy R**, Clayberger C, Krensky A. Tumor specific, cytotoxic T lymphocyte response after 'idiotype' vaccination for B cell, non-Hodgkin's lymphoma. **Blood** 88:580-589, 1996.
157. Syrengelas A, Chen T and **Levy R** DNA Immunization Induces Protective Immunity against B Cell Lymphoma. **Nature Medicine** 2:1038-1041, 1996.
158. Hakim I, Levy S and **Levy R** A Nine Amino Acid Peptide from IL-1B Augments Anti Tumor Immune Responses Induced by Protein and DNA Vaccines. **J Immunol**, 157:5503-5511, 1996.

1997

159. Hsu F, Caspar C, Czerwinski D, Kwak L, Liles T, Syrengelas A, Taidi-Laskowski B, and **Levy R** Tumor-Specific idiotype vaccines in the treatment of patients with B cell lymphoma-long term results of a clinical trial. **Blood**, 89:3129-3135, 1997.
160. Maloney D, White C, Bodkin D, Liles TM, Royston I, Grillo-Lopez, and **Levy R** IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients with Relapsed Non-Hodgkin's Lymphoma. **J Clinical Oncology**, 15: 3266-3274, 1997.

161. Maloney D, Grillo-Lopez A, White C, Bodkin D, Schilder R, Neidhart J, Janakiraman N, Foon K, Liles T, Royston I, Davis T, and **Levy R** IDEC-C2B8 (Rituximab) Anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. **Blood**, 90:2188-2195, 1997.
162. Caspar C, Levy S, and **Levy R** Idiotypic vaccines for non-Hodgkins lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: Comparison of different vaccine formulations. **Blood**, 90:3699-3706, 1997.
162. Okada C, Wong C, Denney D. and **Levy R** T cell antigen receptor vaccines for active immunotherapy of T cell malignancies. **J Immunol**, 159:5516-5527, 1997.

1998

163. Renschler MF, Dower WJ, and **Levy R** Identification of peptide ligands for the antigen binding receptor expressed on Human B-cell lymphomas. **Methods Mol Biol**, 87:209-234, 1998.
164. Haimovich J, Czerwinski D, Wong C, and **Levy R** Determination of anti-idiotypic antibodies by surface plasmon resonance. **J Immunol. Methods**, 214:113-119, 1998.
165. McLaughlin P, Grillo-Lopez A, Link B, **Levy R**, Czuczman M, Williams M, Heyman M, Bence-Bruckler I, White C, Cabanillas F. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a 4-dose treatment program. **J of Clinical Oncology**, 16:2825-2833, 1998.
166. Davis TA, Maloney DG, Czerwinski DK, Liles TM and **Levy R** Anti-Idiotypic antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. **Blood**, 92:1184-1190, 1998.
167. McCormick A, Kumagai M, Hanley K, Turpen T, Hakim I, Grill L, Tuse D, Levy S, and **Levy R** Rapid Production of specific vaccines for lymphoma by expression of the tumor derived single chain Fv epitopes in tobacco plants. **Proc. Natl. Acad. Sci.**, 96:703-708, 1998.

1999

168. Reichardt V, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, and **Levy R** Idiotypic vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-A feasibility study. **Blood**, 93:2411-2419, 1999.
169. Davis T, Czerwinski D, and **Levy R** Therapy of B cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. **Clin Cancer Res**, 5(3):611-615, 1999.
170. Wong C, Okada CY, and **Levy R** TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response. **J of Immunol**, 162:2251-2258, 1999.
171. Syrengelas A and **Levy R** DNA vaccination against the idiotypic of a murine B cell lymphoma: Mechanism of tumor protection. **J of Immunol**, 162:4790-4795, 1999.
172. Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, Dowden S, and **Levy R** Single agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a Phase II trial of Rituximab. **J of Clin Onc**, 17:1851-1857, 1999.
173. Alizadeh A, Eisen M, David RE, Ma C, Sabet H, Tran T, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Chan WC, Greiner T, Weisenburger D, Armitage JO, Lossos I, **Levy R**, Botstein D, Brown PO, and Staudt LM. The Lymphochip: A specialized cDNA microarray for the genomic-

scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harbor Proc. Symp. **Quant. Biol.**, 1999.

2000

174. Lossos I and **Levy R** Mutation Analysis of the 5' Noncoding Regulatory Region of the BCL-6 Gene in Non-Hodgkin's Lymphoma: Evidence for Recurrent Mutations and Intracлонаl Heterogeneity. **Blood**, 95(4):1400-1405, 2000.
175. Alizadeh A, Eisen M, Davis RE, Ma C, Lossos I, Rosenwald A, Boldrick J, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan W, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, **Levy R**, Wilsone W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. **Nature**, 403: 503-511, 2000.
176. Lossos, IS, Okada CY, Tibshirani R, Warnke R, Vose JM, Greiner TC, and **Levy R** Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. **Blood**, 95(5): 1797-1803, 2000.
177. Davis TA, Maloney DG, Grillo-Lopez AJ, White CA, Williams ME, Weiner GJ, Dowden S, and **Levy R** Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with Rituximab and Interferon Alfa-2A. **Clin. Cancer Research**, 6: 264 4-2652, 2000.
178. Timmerman JM and **Levy R** Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. **J. Immunol.** 164(9): 4797-803, 2000.
179. Wong CP and **Levy R** Recombinant adenovirus vaccine encoding a chimeric TCR induces protective immunity against a T cell lymphoma. **Cancer Res.** 60(10):2689-95, 2000.
180. Lossos IS, Alizadeh AA, Eisen MB, Chan WC, Brown PO, Botstein D, Staudt LM, **Levy R** Ongoing immunoglobulin heavy chain somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc. **Nat. Acad. Sciences.** 97: 10209-10213, 2000.
181. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, **Levy R** Rituximab Anti CD20 Monoclonal antibody therapy in non-Hodgkin's lymphoma: the safety and efficacy of re-treatment. **J. Clin. Onc.**18(17):3135-43, 2000.
182. Lossos IS, Tibshirani R, Narasimhan B and **Levy R** The inference of antigen selection on immunoglobulin genes. **J Immunol** 165: 5122-5126, 2000.
183. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, Benike CJ, Reichardt V, van Beckhoven A, Rajapaksa R, Engleman EG, Blume KG, **Levy R** Idiotypic vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. **Biol Blood Marrow Transplant** 6:621-627, 2000.
184. Hastie T, Tibshirani R, Eisen MB, Alizadeh A, **Levy R**, Staudt L, Chan WC, Botstein D and Brown P. 'Gene Shaving' as a Method for Identifying Distinct Sets of Genes with Similar Expression Patterns. **GenomeBiology** 2000;1(2)Research0003.Epub 2000 Aug
185. Lossos IS, Jacobs Y, Cleary ML, **Levy R** Re: Akasaka, H., et al., Molecular anatomy of BCL6 translocations revealed by long-distance polymerase chain reaction-based assays. **Cancer Res.**, 60: 2335-2341, 2000.

2001

186. Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J, [Immunotherapy of Non-Hodgkin's lymphomas](#). Hematology Am Soc Hematol Educ Program. 2001:221-40. PMID: 11722986
187. Timmerman JM, Caspar CB, Lambert SL, Syrengelas AD and **Levy R** Idiotypic-Encoding Recombinant Adenoviruses Provide Protective Immunity against Murine B-Cell Lymphomas. **Blood** 97(5):1370-1377, 2001.
188. Maecker HT, Auffermann-Gretzinger S, Nomura LE, Liso A, Czerwinski DK, **Levy R** Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry. **Clinical Cancer Research** 7: 902s-908s, 2001.
189. Lossos IS, Jones CD, Warnke R, Zehnder JL, Tibshirani R, **Levy R** The expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. **Blood** 98: 945-951, 2001.
190. Cantwell MJ, Wierda WG, Lossos IS, **Levy R**, Kipps TJ. T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154. **Leukemia** 15:1451-1457, 2001.
191. Weng WK, **Levy R** Expression of complement inhibitors CD46, CD55, CD59 on tumor cells does not predict clinical outcome following Rituximab treatment in follicular non-Hodgkin's lymphoma. **Blood** 98(5):1352-1357, 2001.
192. Lossos IS, Jones CD, Zehnder JL, **Levy R** A polymorphism in the BCL-6 gene is associated with follicle center lymphoma. **Lymphoma & Leukemia**, 42:1343-1350,2001.
193. Davis TA, Hsu FJ, Caspar CB, van Beckhoven A, Czerwinski DK, Liles T, Taidi B, Benike CJ, Engleman EG, **Levy R** Idiotypic vaccination following ABMT can stimulate specific anti-idiotypic immune responses in patients with B-cell lymphoma. **Biol Blood Marrow Transplant**, 7:517-522, 2001.

2002

194. Briones J, Timmerman JM, Hilbert DM, **Levy R** BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp. **Hematology**, 30:135-141, 2002.
195. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TA, Engleman EG, **Levy R** Idiotypic-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. **Blood**, 99:1517-1526, 2002.
196. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD, Pickering DL, Lynch JC, Armitage JO, Warnke RA, Alizadeh AA, Lossos IS, **Levy R**, Chan WC. The t(14;18) defines a unique subset of diffuse large B cell lymphoma with a germinal center B cell expression profile. **Blood**, 99:2285-2290, 2002.
197. Auffermann-Gretzinger S, Lossos IS, Vayntrub TA, Leong W, Grumet FC, Blume KG, Stockerl-Goldstein KE, **Levy R**, Shizuru JA. Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic transplant recipients. **Blood**, 99:1442-8, 2002.
198. Lossos IS, Alizadeh AA, Diehm M, Warnke R, Thorstenson Y, Oefner PJ, Brown PO, Botstein D, **Levy R**, Transformation of Follicular Lymphoma to Diffuse Large Cell Lymphoma: Alternative Patterns with Increased or Decreased Expression of *c-myc* and its Regulated

genes. Proceedings of the National Academy of Sciences, **Proc Natl Acad Sci U S A.** 99:8886-91, 2002.

199. Briones J, Timmerman JM, **Levy R** *In vivo* antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. **Cancer Research.** 62, 3195-9, June 2002.
200. Lossos IS, Thorstenson YR, Wayne TL, Oefner PJ, **Levy R**, Chu G. Mutation of the ATM gene is not involved in the pathogenesis of either follicle center lymphoma or its transformation to higher-grade lymphoma. **Leukemia and Lymphoma.** 43, 1079-85, 2002.
201. Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, van Beckhoven A, Norman J, and **Levy R** Immunogenicity of a plasmid DNA vaccine encoding chimeric Idiotypic in patients with B-Cell lymphoma. **Cancer Research.** 62, 5845-52, 2002.
202. Lossos IS, Natkunam Y, **Levy R**, Lopez CD. Apoptosis Stimulating Protein of p53 (ASPP2) Expression Differs in Diffuse Large B-Cell and Follicular Center Lymphoma: Correlation With Clinical Outcome. **Leukemia and Lymphoma.** 43, 2309-17, 2002.
203. Lossos IS, Warnke R, **Levy R** BCL-6 mRNA expression in higher grade transformation of follicle center lymphoma: correlation with somatic mutations in the 5' regulatory region of the BCL-6 gene. **Leukemia,** 16:1857-62, 2002.

2003

204. Lossos IS, Alizadeh AA, Rajapaksa R, Tibshirani R, and **Levy R** *HGAL* is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. **Blood.** 101:433-40, 2003.
205. Bohen SP, Troyanskaya OG, Alter O, Warnke R, Botstein D, Brown PO, and **Levy R** Variation in gene expression patterns in follicular lymphoma and the response to Rituximab. **PNAS.** 100:1926-30, 2003.
206. Martinez-Climent JA, Alizadeh AA, Segraves R, Blesa D, Rubio-Moscardo F, Albertson DG, Garcia-Conde J, Dyer MJS, **Levy R**, Pinkel D, Lossos IS. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. **Blood,** 101:3109-17, 2003.
207. Briones J, Timmerman JM, Panicalli DL, and **Levy R** Antitumor Immunity After Vaccination With B Lymphoma Cells Overexpressing a Triad of Costimulatory Molecules. **JNCI.** 95:548-55, 2003.
208. Do B, Lossos IS, Thorstenson Y, Oefner PJ, and **Levy R** Analysis of FAS (CD95) Gene Mutations in Higher-Grade Transformation of Follicle Center Lymphoma. **Leukemia & Lymphoma.** 44:1317-23, 2003.
209. Lossos IS, Akasaka T, Martinez-Climent JA, Siebert R, and **Levy R** The *BCL6* gene in B-cell lymphomas with 2q27 translocations is expressed mainly from the rearranged allele irrespective of the partner gene. **Leukemia.** 17:1390-1397, 2003.
210. Akasaka T, Lossos IS and **Levy R** BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. **Blood.** Aug 15;102:1443-8, 2003. Epub 2003 May 08
211. Lossos IS, Czerwinski, DK, Wechser, MA, and **Levy R** Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. **Leukemia.** 17:789-95, 2003.

212. **Levy R.** Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. *Leukemia*. 2003 Apr;17(4):796-7.
213. Akasaka T, Lossos IS, **Levy R.** BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. *Blood*. 2003 Aug 15;102(4):1443-8. Epub 2003 May 08.
214. Lossos IS, **Levy R.** Diffuse large B-cell lymphoma: insights gained from gene expression profiling. *Int J Hematol*. 2003 May;77(4):321-9. Review.
215. McCormick AA, Reinl SJ, Cameron TI, Vojdani F, Fronefield M, **Levy R**, Tuse D. Individualized human scFv vaccines produced in plants: humoral anti-idiotypic responses in vaccinated mice confirm relevance to the tumor Ig. *J Immunol Methods*. 2003 Jul;278(1-2):95-104.
216. Weng WK, **Levy R** Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. *J Clin Oncol*. 2003 Nov 1;21(21):3940-7.
217. Lossos IS, **Levy R** Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. *Cancer Biology* 13:191-202, 2003

2004

218. Lambert SL, Okada CY, **Levy R** TCR vaccines against a murine T cell lymphoma: a primary role for antibodies of the IgG2c class in tumor protection. *J Immunol*. 2004 Jan 15;172(2):929-36.
219. Reddy S, **Levy R** Molecular rescue of tumor-specific T cell receptor idiotype from T cell lymphomas, *Br J Haematol*. 2004 Mar;124(5):626-8
220. Lossos IS, Czerwinski D, Alizadeh A., Wecheser M, Tibshirani R, Botstein D, **Levy R** Prediction of survival in diffuse large B-cell lymphoma based on the expression of six genes. *New England Journal of Medicine*, 350:1828-37, 2004 .
221. Lossos IS, **Levy R**, Alizadeh AA, AID is expressed in germinal center B cell-like and activated B-cell like diffuse large cell lymphomas and is not correlated with intraclonal heterogeneity. *Leukemia* November 2004, Volume 18, Number 11, Pages 1775-1779
222. Yang J, Kanter G, Voloshin A, **Levy R**, Swartz JR. Expression of Active Murine Granulocyte Macrophage Colony-Stimulating Factor in an Escherichia coli Cell-Free system. *Biotechnol Prog* 20 (6): 1689-96, 2004.
223. Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, Wahl RL, Kroll S, Coleman, M, Goris M, **Levy R**, Knox SJ. The radioisotope contributes significantly to the activity of radioimmunotherapy. *Clin Cancer Res* 10 (23): 7792-8, 2004.
224. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, **Levy R.** Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. *J Clin Oncol*. 2004, 22:4665-72.

2005

225. Yang, J., Kanter, G., Voloshin, A., Michel-Reydellet, N., Velkeen, H., **Levy, R.** and Swartz, J.R., Rapid Expression of Vaccine Proteins for B Cell Lymphoma in a Cell-free System *Biotechnology and Bioengineering*, Vol. 89, p 503-511, 2005.

226. Natkunam Y, Lossos IS, Behnaz T, Zhao S, Lu X, Ding F, Hammer S, Marafioti T, Byrne GE, Levy S, Warnke RA, **Levy R**. Expression of the Human Germinal Center-Associated Lymphoma (HGAL) Protein, A New Marker of Germinal Center B Cell Derivation, **Blood**. 2005 Jan 27
227. Song W, **Levy R**. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. **Cancer Res** 65 (13): 5958-64, 2005.

2006

228. Guardino AE, Rajapaksa R, Ong KH, Sheehan K, **Levy R**. Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma. **Cytotherapy** 8 (3): 277-89, 2006.
229. Irish JM, Czerwinski DK, Nolan GP, **Levy R**. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. **Blood** 108 (9): 3135-42, 2006. PMID: 16835385
230. Irish JM, Czerwinski DK, Nolan GP, **Levy R**. Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. **J Immunol** 177 (3): 1581-9, 2006.

2007

231. Kanter G, Yang J, Voloshin A, Levy S, Swartz JR, **Levy R**. Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. **Blood** 109 (8): 3393-9, 2007. PMID: 17164345
232. Natkunam Y, Hsi ED, Aoun P, Zhao S, Elson P, Pohlman B, Naushad H, Bast M, **Levy R**, Lossos IS. Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival. **Blood** 109 (1): 298-305, 2007. PMID: 18324968
233. Natkunam Y, Vainer G, Chen J, Zhao S, Marinelli RJ, Hammer AS, Hamilton-Dutoit S, Pikarsky E, Amir G, **Levy R**, Yisraeli JK, Lossos IS. Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms. **Haematologica** 92 (2): 176-83, 2007. PMID: 17296566
234. Natkunam Y, Zhao S, Mason DY, Chen J, Taidi B, Jones M, Hammer AS, Hamilton Dutoit S, Lossos IS, **Levy R**. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. **Blood** 109 (4): 1636-42, 2007. PMID: 17038524
235. Weng WK, Czerwinski D, **Levy R**. Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. **Blood** 109 (3): 951-3, 2007. PMID: 17032925
236. Aichun Liu, Alice Guardino, Lek Chinsangaram, Matthew J. Goldstein, Dennis Panicali and **Levy R**, Therapeutic Vaccination against Murine Lymphoma by Intratumoral Injection of Recombinant Fowlpox Virus Encoding CD40 Ligand, **Cancer Res**. 2007 Jul 15;67(14):7037-44 PMID: 17638917

237. Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, Krieg AM, **Levy R.**, Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires Expression of the Toll Like Receptor 9, either in the host or on the tumor itself. **J. Immunol** 2007 179:2493-2500. PMID: 17675511
238. Weinberg OK, Ai WZ, Mariappan MR, Shum C, **Levy R**, Arber DA, 'Minor' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases. **J Mol Diagn.** 2007 Sep;9(4):530-7. PMID: 17652637

2008

239. Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, **Levy R**, Gascoyne RD, Lossos IS. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. **J Clin Oncol.** 2008 Jan 20;26(3):447-54. PMID: 18086797
240. Baecklund, Eva, Natkunam, Yasodha, Backlin, Carin, Iliadou, Anastasia, Askling, Johan, Ekblom, Anders, Feltelius, Nils, Klareskog, Lars, Enblad, Gunilla, Lossos, S Izidore, **Levy, Ronald**, Sundstrom, Christer, Rosenquist, Richard. Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis. **British Journal of Haematology**, Vol. 141, No. 1. (April 2008), pp. 69-72. PMID: 18324968
241. Raquel Malumbres, Jun Chen, Rob Tibshirani, Nathalie A. Johnson, Laurie H. Sehn, Yaso Natkunam, Javier Briones, Ranjana Advani, Joseph M. Connors, Gerald E. Byrne, **Ronald Levy**, Randy D. Gascoyne, and Izidore S. Lossos Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP **Blood**, Jun 2008; 111: 5509 - 5514. PMID: 18445689
242. McCormick AA, Reddy S, Reinl SJ, Cameron TI, Czerwinski DK, Vojdani F, Hanley KM, Garger SJ, White EL, Novak J, Barrett J, Holtz RB, Tusé D, **Levy R**. Plant-produced idiotypic vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study. **Proc Natl Acad Sci U S A.** 2008 Jul 22;105(29):10131-6. PMID: 18645180

2009

243. Ai WZ, Hou JZ, Zeiser R, Czerwinski D, Negrin RS, **Levy R**. Follicular lymphoma B cells induce the conversion of conventional CD4(+) T cells to T-regulatory cells. **. Int J Cancer.** 2009 Jan 1;124(1):239-44. PMID: 18814264
244. Houot R, **Levy R**. Idiotypic vaccination for lymphoma: moving towards optimisation. **Leuk Lymphoma.** 2009 Jan;50(1):1-2 PMID: 19172492
245. Brody JD, Goldstein MJ, Czerwinski DK, **Levy R**. Immunotransplant preferentially expands T effector cells over Tregulatory cells and cures large lymphoma tumors. **Blood.** 2009 Jan 1;113(1):85-94. PMID: 18812472
246. Timmerman JM, Vose JM, Czerwinski DK, Weng WK, Ingolia D, Mayo M, Denney DW, **Levy R**. Tumor-specific recombinant idiotypic immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. **Leuk Lymphoma.** 2009 Jan;50(1):37-46. PMID: 19125383

247. Gratzinger D, Zhao S, West R, Rouse RV, Vogel H, Gil EC, **Levy R**, Lossos IS, Natkunam Y. The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. **Am J Clin Pathol**. 2009 Feb;131(2):264-78. PMID: 19141387
248. Weiyun Z. Ai, Robert Tibshirani, Behnaz Taidi, Debra Czerwinski, and **Ronald Levy**, Anti-idiotypic antibody response after vaccination correlates with better overall survival in follicular lymphoma. **Blood**. 2009 Jun 4;113(23):5743-6. PMID: 19346494
249. Roch H., **Levy R**. T cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. *Blood*, 9 April 2009, Vol. 113, No. 15, pp. 3546-3552. PMID: 18941113
250. Weng WK, **Levy R**. Genetic polymorphism of the inhibitory IgG Fc receptor FcγRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab **Leuk Lymphoma**. 2009 May;50(5):723-7. PMID: 19452316
251. Houot R, **Levy R**. Vaccines for lymphomas: idiotypic vaccines and beyond, **Blood Rev**. 2009 May;23(3):137-42 PMID: 18951668
252. Alizadeh AA, Gentles AJ, Lossos IS, **Levy R**. Molecular outcome prediction in diffuse large-B-cell lymphoma. **N Engl J Med**. 2009 Jun 25;360(26):2794-5. PMID: 19553658
253. Varghese B, Widman A, Do J, Taidi B, Czerwinski DK, Timmerman J, Levy S, **Levy R**. Generation of CD8+T cell-mediated immunity against idiotype negative lymphoma escapees. **Blood**. 2009 Sep 17. PMID: 19762487
254. Gentles AJ, Alizadeh AA, Lee SI, Myklebust JH, Shachaf CM, Shahbaba B, **Levy R**, Koller D, Plevritis SK, A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. **Blood**. 2009 Oct 8;114(15):3158-66. PMID: 19636063
255. Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT, Irish JM, Torchia JA, Kolstad A, Chen L, **Levy R**, Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion., **Blood**. 2009 Oct 15;114(16):3431-8. PMID: 19641184
256. Weng WK, **Levy R**, Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma.. **Leuk Lymphoma**. 2009 Sep;50(9):1494-500. PMID: 19672774
257. Patel KG, Ng PP, Kuo CC, Levy S, **Levy R**, Swartz JR, Cell-free production of Gaussia princeps luciferase--antibody fragment bioconjugates for ex vivo detection of tumor cells. **Biochem Biophys Res Commun**. 2009 Dec 18;390(3):971-6. PMID: 19852937**2010**

2010

258. Luo RF, Zhao S, Tibshirani R, Myklebust JH, Sanyal M, Fernandez R, Gratzinger D, Marinelli RJ, Lu ZS, Wong A, **Levy R**, Levy S, Natkunam Y, CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. **Hum Pathol**. . [Epub ahead of print] PMID: 20004001 PMCID: PMC2813949

259. Anderson MW, Zhao S., Ai WZ, Tiberirani R, **Levy R.** Lossos IS, Natkunam Y. C-C chemokine receptor 1 expression in human hematolymphoid neoplasia. *Am J Clin Pathol.* 2010; 133 (3): 473-83. PMID 20154287
260. Irish JM, Myklebust JH, Alizadeh AA, Houot R, Sharman JP, Czerwinski DK, Nolan GP, **Levy R.**, Inaugural Article: B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. *Proc Natl Acad Sci U S A.* 2010 Jun 11. PMID 20543139
261. Joshua D. Brody, Weiyun Z. Ai, Debra K. Czerwinski, James A. Torchia, Mia Levy, Ranjana H. Advani, Youn H. Kim, Richard T. Hoppe, Susan J. Knox, Lewis K. Shin, Irene Wapnir, Robert J. Tibshirani, Ronald Levy, In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study, *J. Clin Onc.* June 16 2010 PMID: 20697067
262. Younes SF, Beck AH, Lossos IS, Levy R, Warnke RA, Natkunam Y. Immunoarchitectural patterns in follicular lymphoma: efficacy of HGAL and LMO2 in the detection of the interfollicular and diffuse components. *Am J Surg Pathol.* 2010 Sep;34(9):1266-76. PMCID: PMC2929284
263. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. *Cell.* 2010 Sep 3;142(5):699-713. PMID: 20813259
264. Patel KG, Ng PP, Levy S, Levy R, Swartz JR, Escherichia coli-based production of a tumor idiotype antibody fragment - tetanus toxin fragment C fusion protein vaccine for B cell lymphoma., *Protein Expr Purif.* 2011 Jan;75(1):15-20. Epub 2010 Sep 19. PMID: 20851769
265. Goldstein MJ, Varghese B, Brody JD, Rajapaksa R, Kohrt H, Czerwinski DK, Levy S, Levy R, A CpG-loaded tumor cell vaccine induces anti-tumor CD4+ T cells that are effective in adoptive therapy for large and established tumors, *Blood.* 2010 Sep 27. [Epub ahead of print] PMID: 20876455

BOOK CHAPTERS/REVIEW ARTICLES

1977

1. Klinman NR, Segal GP, Gerhard W, Braciale T and **Levy R:** Obtaining homogeneous antibody of desired specificity from fragment cultures. **Antibodies in Human Diagnosis and Therapy.** E Haber and RM Krause (eds.), Raven Press, NY, pp. 225–236, 1977.

1978

2. Weissman IL, Warnke R, Butcher EC, Rouse R and **Levy R:** The lymphoid system: Its normal architecture and the potential for understanding the system through the study of lymphoproliferative diseases. **Human Pathology**, Volume 9, Number 1, pp. 25–45, January 1978.
3. Kaplan HS and **Levy R**, eds. **Malignant Lymphoma.** UICC Technical Report Series, Volume 37, Geneva, 239p, 1978.

4. **Levy R**, Dilley J and Lampson LA: Human normal and leukemia cell surface antigens. Mouse monoclonal antibodies as probes. **Lymphocyte Hybridomas: Current Topics In Microbiology and Immunology**, Volume 81. F Melchers, M Potter and N Warner (eds.), Springer-Verlag, Berlin, pp. 164–169, 1978.
5. **Levy R**, Dilley J, Siora K and Kucherlapati R. Mouse-human hybridomas. The conversion of non-secreting human B cells into Ig secretors. **Lymphocyte Hybridomas: Current Topics in Microbiology and Immunology**, Volume 81. F Melchers, M Potter and N Warner (eds.), Springer-Verlag, Berlin, pp. 170–172, 1978.

1980

6. Goodenow RS, Brown S, **Levy R** and Kaplan HS: Partial characterization of the virion proteins of a type-C RNA virus produced by a human histiocytic lymphoma cell line. **Viruses In Naturally Occurring Cancers**. Cold Spring Harbor Conferences on Cell Proliferation, Volume 7, Cold Spring Harbor Laboratory, pp. 737–752, 1980.
7. **Levy R**, Dilley J, Brown S and Bergman Y: Mouse x human hybridomas. **Monoclonal Antibodies**, Chapter 9. RH Kennett, TJ McKearn and KB Bechtol (eds.), Plenum Publishing Corporation, New York, pp. 137–249, 1980.
8. Warnke R and **Levy R**: Tissue section immunologic methods in lymphomas. Chapter 12. **Diagnostic Immunohistochemistry**, pp. 203–211, 1980.

1982

9. **Levy R**, Hatzubai A, Brown S, Maloney D and Dilley J: Immunoglobulin idiotype: A tumor-specific antigen for human B-cell lymphomas. **Malignant Lymphomas**. Chapter 5. Academic Press, Inc., pp. 95–105, 1982.
10. Fox R, Baird S, Kung P, **Levy R** and Royston I: Cell surface antigens on normal and neoplastic human lymphoid cells. **Human Cancer Markers**. Chapter 2. S Sell and B Wahren (eds.), Humana Press, pp. 33–68, 1982.
11. Miller RA, Stratte PT, Oseroff AR, Link MP and **Levy R**: Treatment of human T-cell lymphomas and leukemias with monoclonal anti-T cell antibodies. **Hybridomas in Diagnosis and Treatment**. Ortho Pharmaceutical Ltd., Canada, pp. 105–110, 1982.
12. **Levy R**: Monoclonal antibodies in clinical trials of human T and B cell malignancies. **Biological Response Modifiers Program**. Proceedings of the Retreat on Monoclonal Antibodies in Therapeutic Trials. Frederick, Maryland, pp. 53–55, 1982.
13. Miller RA, Maloney D, Warnke R, McDougall R, Wood G, Kawakami T, Dilley J, Goris ML and **Levy R**: Considerations for treatment with hybridoma antibodies. **Hybridomas in Cancer Diagnosis and Treatment**. MS Mitchell and HF Oettgen (eds.), Raven Press, New York, pp. 133–145, 1982.
14. **Levy R**: Monoclonal antibodies: Sixth Annual Cancer Symposium, **Scripps Memorial Hospital**, 1982.

1983

15. Finn OJ, Sung E, Jones P and **Levy R**: Two alpha chains and three beta chains of human Ia antigen. In: **Ir Genes: Past Present and Future**. CW Pierce, SE Cullen JA Kapp, BD Schwartz and DC Shreffler, editors. Humana Press, Clifton, NJ, pp. 203–207, 1983.

16. **Levy R**, Stratte PT, Link MP, Oseroff A, Maloney DG and Miller RA: Monoclonal antibodies in leukemia therapy. **Leukemia Research: Advances in Cell Biology and Treatment**. SB Murphy and JR Gilbert, editors. Elsevier Science Publishing Co., pp. 269–279, 1983.
17. Hurley CK, Nunez G, Winchester R, Finn O, **Levy R**, Stastny P and Capra JD: Partial structural characterization of human HLA-DR subsets using monoclonal antibodies. **Hybridomas and Cellular Immortality**. BH Tom and JP Allison, editors. Plenum Publishing Corporation, NY, pp. 83–100, 1983.
18. **Levy R**, Miller RA, Stratte PT, Maloney DG, Link MP, Meether TC, Oseroff A, Thielemans K and Warnke R: Therapeutic trials of monoclonal antibody in leukemia and lymphoma: Biologic considerations. **Monoclonal Antibodies and Cancer**. RE Langman, IS Trowbridge and R. Dulbecco, editors. **Academic Press**, NY, pp. 5–16, 1983.
19. **Levy R** and Miller RA: Biological and clinical implications of lymphocyte hybridomas: Tumor therapy with monoclonal antibodies. **Ann Rev Med** **34**:107–116, 1983.
20. **Levy R**: Monoclonal antibodies in cancer therapy. **Clinical Immunology Today**, No. 3., pp. 1–7. July 1983.

1984

21. **Levy R**, Stratte P, Link M, Maloney DG, Oseroff A and Miller RA: Monoclonal antibodies to human lymphocytes. **Monoclonal Antibodies and Functional Cell Lines**. Chapter 8. RH Kennett, KB Bechtol and TJ McKearn (eds.), Plenum Publishing Corporation, New York, pp. 193–214, 1984.

1985

22. **Levy R**: Biologicals for cancer treatment: Monoclonal antibodies. **Cancer: Progress and Prospects XXVII. Hospital Practice**, pp. 67–92, November 15, 1985.
23. Lowder JN and **Levy R**: Monoclonal antibodies—therapeutic and diagnostic uses in malignancy. **Western J Med** **143**:810–818, December 1985.
24. Miller RA and **Levy R**: Functional and surface marker characteristics. **Immunoglobulin: A Tumor Specific Antigen for Human B Cell Lymphoma**. Academic Press, 1985.
25. Lowder JN, Meeker TC and **Levy R**: Monoclonal antibody therapy of lymphoid malignancy. **Cancer Surveys** **4**:359–375, 1985.

1986

26. **Levy R**, Meeker T, Lowder J, Maloney D, Thielemans K, Gralow J, Warnke RA, Miller RA, Cleary ML and Sklar J: The immunobiology of B cell lymphoma studies with anti-idiotypic antibodies. **Symposium on Fundamental Cancer Research**, Vol. 38, pp. 261–268, 1986, University of Texas System Cancer Center.

1987

27. **Levy R**: Monoclonal antibodies: Clinical trials and new insights into tumour biology. **A Perspective on Biology and Medicine in the Twenty-First Century**, Royal Society of Medicine Services Limited, Series 121, pp. 103–112, 1987.
28. **Levy R**, Levy S, Brown SL, Kon S and Carroll W: Anti-idiotypic antibodies reveal the existence of somatic mutation in human B cell lymphoma. **Monographs in Allergy**. P Dukor, LA Hanson, P Kallos, F Shakib, Z Trnka and BH Waksman (eds.), S. Karger, Basel,

22:194–203, 1987.

- 29. **Levy R**, Levy S, Cleary ML, Carroll W, Kon S, Bird J and Sklar J: Somatic mutation in human B cell tumors. **Immunological Reviews** 96:43–58, Munksgaard, Copenhagen, 1987.
- 30. **Levy R**: Will monoclonal antibodies find a place in our therapeutic armamentarium? **J Clin Oncology** 5:527–529.

1989

- 31. Brown SL, Miller RA and **Levy R**: Anti-idiotype antibody therapy of B-cell lymphoma. **Seminars in Oncology** 16:199–210, 1989.
- 32. Campbell MJ, Esserman L, Byars NE, Allison AC and **Levy R**: Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor. **Intern. Rev. Immunol** 4:251, 1989.

1990

- 33. **Levy, R.** and Miller RA: Therapy of lymphoma directed at idiotypes. **NCI Monographs**, 10:61–68, 1990.
- 34. Miller R and **Levy R**: Radiolabeled antibodies: Another form of cytotoxic treatment. **J Clin Onc** 9:537–538, 1990.
- 35. Kwak LW, Campbell M, and **Levy R** Idiotypic vaccination post-bone marrow transplantation for B-cell lymphoma: Initial Studies in a murine model. **Cancer Detection and Prevention** 15:323–325, 1990.
- 36. **Levy R**: Anti-idiotypes: Therapy and somatic mutation of human B cell tumors. **Immunology for the Practicing Physician**. Bozell, Jacobs, Kenyon and Echardt, Inc., New York, 1990.
- 37. Campbell MJ, Brown SL and **Levy R**: Tumor immunology and immunotherapy. **Immunology Scope Monograph**. Upjohn Co., Kalamazoo, Michigan, 1990.
- 38. **Levy R** and Miller RA: Antibodies in cancer therapy: B cell lymphomas. **Biologic Therapy of Cancer: Principles and Practice**, S Hellman, V DeVita and SA Rosenberg (eds), Lippincott, 1990.

1991

- 39. Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Nelp WB, **Levy R**, Miller R, Fisher D, Matthews D, and Bernstein ID: Radiolabeled antibody therapy of human B cell lymphomas. **Immunobiology of Proteins and Peptides VI**, M.Z. Atassi (ed), Plenum Press, 1991.

1992

- 40. Bahler DW, Zelenetz AD, Chen TT and **Levy R**, Antigen selection in human lymphomagenesis. **Cancer Research (Suppl)** 52:5547a–5551s, 1992.
- 41. Maloney DG, **Levy R**, and Miller RA. Monoclonal anti-idiotype antibody therapy of lymphoma. **Biologic Therapy of Cancer Update**, V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), J.B. Lippincott Company, Philadelphia, PA, 1992.

1993

42. Renschler MF and **Levy R** Overcoming the limitations of chemotherapy in the treatment of B-cell Non-Hodgkin's lymphomas—An approach using radiolabeled peptide ligands. **Western J. Med.** 158:530–532, 1993.

1994

43. Maloney DG, **Levy R**, and Campbell MJ. Antibodies. **The Molecular Basis of Cancer**, J. Mendelsohn, PM Howley, MA Israel, LA Liotta (eds.), WB Saunders, Harcourt Brace Jovanovich, Inc. , Philadelphia, PA. 1994

1995

44. Renschler MF, Dower WJ, **Levy R** Identification of Peptide Ligands for the Antigen Binding Receptor Expressed on Human B-Cell Lymphomas. **Combinatorial Peptide Libraries, Methods in Molecular Biology**, Humana Press, Inc., Totowa, NJ. 1995

1997

45. Hsu F, Engleman E and **Levy R** Dendritic cells and their application in immunotherapeutic approaches to cancer therapy. **PPO Updates**, Vol 11, No. 5, 1997
46. Reichardt V, Okada C, Stockerl-Goldstein K, Bogen B, and **Levy R** Rationale for adjuvant idiotypic vaccination after high dose therapy for multiple myeloma. **Biology of Blood & Marrow Transplantation**, 3:157-163, 1997
47. Maecker HT, Syrengelas A and **Levy R** Cytokine fusion constructs as DNA vaccines against tumors. **Methods in Molecular Medicine**, 29:221-239, 1997

1998

48. Timmerman J and **Levy R** Melanoma vaccines: Prim and proper presentation. **Nature Medicine**, 4:6-7, 1998.

1999

49. Timmerman JM and **Levy R** Dendritic cell vaccines for cancer immunotherapy. **Ann Rev of Med**, 50:507-529, 1999.
50. **Levy R** Karnofsky Lecture: Immunotherapy of lymphoma. **J. Clinical Oncology**. 17(11 Suppl):7-12, 1999.
51. Alizadeh A, Eisen M, Davis RE, Ma C, Sabet H, Tran T, Powell JI, Yang L, Marti GE, Moore DT, Hudson JR Jr, Chan WC, Greiner T, Weisenburger D, Armitage JO, Lossos I, **Levy R**, Botstein D, Brown PO, Staudt LM. Related Articles. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. **Cold Spring Harb Symp Quant Biol**. 64:71-8, 1999.

2000

52. **Levy, R.** A perspective on monoclonal antibody therapy: Where we have been and where we are going. **Seminars in Hematology**, 37 (suppl. 7), 2000.
53. Timmerman J, and **Levy R** The history of the development of vaccines for the treatment of lymphoma. **Clinical Lymphoma**, 1(2): 129-139, 2000.
54. **Levy, R.** Monoclonal antibodies for the treatment of lymphoma; many different ways to use a new modality. **Hematology 2000**, 397-400, 2000.

2001

- 55. Reddy SA, Okada C, Wong C, Bahler D, **Levy R** T cell antigen receptor vaccines for active therapy of T cell malignancies. Cutaneous T Cell Lymphoma: Basic and Clinically Relevant Biology, Ann N Y Acad Sci. 941:97-105, 2001.
- 56. Press OW, Leonard JP, Coiffier B, **Levy R**, Timmerman J. Immunotherapy of Non-Hodgkin's Lymphomas, **Hematology** (Am Soc Hematol Educ Program) 221-40, 2001.

2003

- 57. Lossos IS and **Levy, R**. Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. **Semin Cancer Biol.** 2003 Jun;13(3):191-202.
- 58. Lossos IS and **Levy R** Diffuse Large B-cell Lymphoma: insights gained from gene expression profiling. International Journal of Hematology. Int. **J. Hematol.** 77:321-9, 2003.

2008

- 59. Houot R, **Levy R**, Vaccines for lymphomas: Idiotypic vaccines and beyond, Blood Reviews (2008), doi:10.1016/j.blre.2008.09.001
- 60. Houot R, **Levy R**. Therapeutic vaccine for lymphoma: lessons learned and future directions. Am Assoc Cancer Res Educ Book 2008: 3-11.

2009

- 61. Houot R, **Levy R**, Idiotypic vaccination for lymphoma: moving towards optimization, Leukemia & Lymphoma, January 2009; 50(1): 1–2
- 62. Alizadeh AA, Gentles AJ, Lossos IS, **Levy R**. Molecular outcome prediction in diffuse large-B-cell lymphoma. N Engl J Med. 2009 Jun 25;360(26):2794-5.